Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VIR-2218 + selgantolimod + nivolumab
- Development stage
- Unknown
- Lead developer
- Vir Biotechnology
- Modality
- Small Molecules, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Oral, Intravenous
01
Overview
This is an **investigational combination regimen** for chronic hepatitis B, comprising three agents: - **VIR-2218** (an RNA interference small interfering RNA [siRNA] designed to target hepatitis B virus RNA, reducing viral replication and antigen expression); - **Selgantolimod** (an oral agonist of Toll-like receptor 8 [TLR8], which modulates innate and adaptive immune responses by enhancing cytokine and chemokine release and activating immune cell subsets); - **Nivolumab** (a monoclonal antibody immune checkpoint inhibitor targeting programmed cell death protein 1 [PD-1], reversing T-cell exhaustion and restoring antiviral immunity). This combination is **being studied for inducing functional cure in chronic hepatitis B** through antiviral, immune stimulation, and immunomodulation approaches. Clinical trial participation includes nucleos(t)ide analogue-treated and viremic hepatitis B subjects. Development is led by Vir Biotechnology (VIR-2218), Gilead Sciences (selgantolimod), and Bristol Myers Squibb (nivolumab/Opdivo), with manufacturing by these respective companies.
- Other names
- SLGNGS-9688GS9688GS 9688Opdivo
02
Targets
TLR8 (Toll-like receptor 8)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on VIR-2218 + selgantolimod + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VIR-2218 + selgantolimod + nivolumab.